Tenderwize
Retour à la recherche

Open House Biologics Discount Contracts 2026-24 - Aflibercept (ATC: S01LA05; Strength: 40 mg/ml)

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2027 · 338 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-24 - Aflibercept (ATC: S01LA05; Wirkstärke: 40 mg/ml)

50/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

The procedure is not a public procurement under EU directives; legal remedies are through social courts, not procuremen...

Missing the monthly deadline (3rd of previous month) may delay pharmacy software listing by one month.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Supply of Aflibercept 40 mg/ml (ATC: S01LA05) under discount contracts
  • Contracts concluded on non-exclusive basis with all eligible pharmaceutical entrepreneurs
Afficher le résumé complet

Open House procedure by Techniker Krankenkasse (TK) for discount contracts on Aflibercept (ATC: S01LA05, 40 mg/ml). Any eligible pharmaceutical entrepreneur can join. No selection, no exclusivity. Contract max 12 months starting 01.08.2026, extendable by 12 months. Value not disclosed.

Risques

The procedure is not a public procurement under EU directives; legal remedies are through social courts, not procuremen...

Missing the monthly deadline (3rd of previous month) may delay pharmacy software listing by one month.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG
  • Must have a valid marketing authorization for the product or be entitled to market it
  • Seat must be in Germany, another EU member state, or EEA state

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Biologics Discount Contracts 2026-24 - Aflibercept (ATC: S01LA05; Strength: 40 mg/ml)

Conclusion of discount contracts with all eligible pharmaceutical entrepreneurs for Aflibercept 40 mg/ml.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jul 2026 - Jul 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jul 30, 2027

Détails de la procédure

Date de publication
04 Jun 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
385850-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3